AR119158A1 - Tratamientos de angioedema hereditario - Google Patents

Tratamientos de angioedema hereditario

Info

Publication number
AR119158A1
AR119158A1 ARP200101681A ARP200101681A AR119158A1 AR 119158 A1 AR119158 A1 AR 119158A1 AR P200101681 A ARP200101681 A AR P200101681A AR P200101681 A ARP200101681 A AR P200101681A AR 119158 A1 AR119158 A1 AR 119158A1
Authority
AR
Argentina
Prior art keywords
hereditary angioedema
treatments
hae
bradykinin
solvate
Prior art date
Application number
ARP200101681A
Other languages
English (en)
Inventor
Edward Paul Feener
Sally Louise Marsh
Christopher Martyn Yea
Andreas Maetzel
Michael David Smith
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of AR119158A1 publication Critical patent/AR119158A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Reivindicación 1: Un método para tratar angioedema hereditario mediado por bradiquinina (HAE) a solicitud, comprendiendo: la administración oral del compuesto de la fórmula (1) (o una sal farmacéuticamente aceptable y/o solvato del mismo) a un paciente que lo necesita a solicitud.
ARP200101681A 2019-06-14 2020-06-16 Tratamientos de angioedema hereditario AR119158A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema

Publications (1)

Publication Number Publication Date
AR119158A1 true AR119158A1 (es) 2021-12-01

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101681A AR119158A1 (es) 2019-06-14 2020-06-16 Tratamientos de angioedema hereditario

Country Status (29)

Country Link
US (1) US20220218680A1 (es)
EP (2) EP3982960B1 (es)
JP (2) JP7356518B2 (es)
KR (1) KR20220024220A (es)
CN (1) CN114126612A (es)
AR (1) AR119158A1 (es)
AU (1) AU2020293614A1 (es)
BR (1) BR112021024664A2 (es)
CA (1) CA3142218A1 (es)
CL (2) CL2021003244A1 (es)
DK (1) DK3982960T3 (es)
EA (1) EA202193019A1 (es)
ES (1) ES2956471T3 (es)
FI (1) FI3982960T3 (es)
GB (1) GB201910116D0 (es)
HR (1) HRP20230696T1 (es)
HU (1) HUE063163T2 (es)
IL (1) IL288615A (es)
LT (1) LT3982960T (es)
MA (1) MA56187B1 (es)
MD (1) MD3982960T2 (es)
MX (1) MX2021014557A (es)
PL (1) PL3982960T3 (es)
PT (1) PT3982960T (es)
RS (1) RS64412B1 (es)
SG (1) SG11202113304YA (es)
SI (1) SI3982960T1 (es)
TW (1) TW202112370A (es)
WO (1) WO2020249977A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4232031A1 (en) * 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
EP4291186A1 (en) 2021-02-09 2023-12-20 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
EP4288036A1 (en) 2022-04-27 2023-12-13 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
HUE057851T2 (hu) 2013-05-23 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorai
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor

Also Published As

Publication number Publication date
MA56187A (fr) 2022-04-20
DK3982960T3 (da) 2023-08-21
KR20220024220A (ko) 2022-03-03
LT3982960T (lt) 2023-08-25
PL3982960T3 (pl) 2024-01-15
EP3982960B1 (en) 2023-06-28
EP4282474A2 (en) 2023-11-29
SG11202113304YA (en) 2021-12-30
AU2020293614A1 (en) 2022-01-27
SI3982960T1 (sl) 2023-10-30
HUE063163T2 (hu) 2023-12-28
HRP20230696T1 (hr) 2023-10-13
CN114126612A (zh) 2022-03-01
MD3982960T2 (ro) 2023-12-31
EP4282474A3 (en) 2024-02-14
BR112021024664A2 (pt) 2022-05-31
MX2021014557A (es) 2022-01-11
US20220218680A1 (en) 2022-07-14
JP2022536287A (ja) 2022-08-15
ES2956471T3 (es) 2023-12-21
PT3982960T (pt) 2023-09-26
IL288615A (en) 2022-02-01
EP3982960A1 (en) 2022-04-20
WO2020249977A1 (en) 2020-12-17
TW202112370A (zh) 2021-04-01
RS64412B1 (sr) 2023-09-29
GB201910116D0 (en) 2019-08-28
CA3142218A1 (en) 2020-12-17
MA56187B1 (fr) 2023-09-27
JP7356518B2 (ja) 2023-10-04
EA202193019A1 (ru) 2022-03-24
JP2023166406A (ja) 2023-11-21
FI3982960T3 (fi) 2023-08-29
CL2023000639A1 (es) 2023-10-30
CL2021003244A1 (es) 2022-09-30

Similar Documents

Publication Publication Date Title
AR119158A1 (es) Tratamientos de angioedema hereditario
AR119159A1 (es) Tratamientos de angioedema
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
ECSP11011030A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
BRPI0517650A (pt) uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2023012095A (es) Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
BR0311747A (pt) Composição farmacêutica, forma de dose simples ou de múltiplas doses da composição, kit, e, método para tratar doença
BR112015012497A2 (pt) combinações farmacêuticas
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
CO2022004947A2 (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.